Open-label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Children With Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-host Disease
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary) ; Mycophenolate mofetil (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 05 Apr 2019 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 29 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.